The exact treatment for PE depends on its severity and whether you need critical treatment in an emergency room setting. PE medications are usually considered before medical procedures.
The trial adds much-needed randomized data to an area where it’s been lacking. Questions about methods muddy interpretation.
KKR's acquisition of SunFireMatrix and Consello's purchase of EHE Health are among the deals that exemplify the new trends.
Julie Bulman, MD, presented the results of the pilot ENGULF trial. The two-phase, prospective, single-arm study assessed the ...
Jupiter Endovascular today announced the first U.S. patient treated in its SPIRARE II U.S. pivotal study for the Vertex ...
Penumbra (PEN) announced new data that demonstrate patients with intermediate-risk pulmonary embolism – PE – treated with ...
A nationwide retrospective study evaluated health care resource utilization and outcomes among patients with ...
(Nasdaq:NARI) today announced positive results from its prospective PEERLESS trial for the FlowTriever system.
In a recent study, an international research team with significant involvement from MedUni Vienna has investigated how ...
“These results are crucial to guiding optimal PE treatment decisions, providing strong evidence that FlowTriever may reduce clinical deterioration and the need for reintervention through more ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback